Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms’ R&D Investment in China? An Event Study Approach

Innovation is the key to the development of the pharmaceutical industry. The pilot program of China’s “4 + 7” volume-based procurement policy (“4 + 7” procurement policy) brings the drug price back to a reasonable level through trading procurement quantities for lower drug prices. The policy manages...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yuanyuan, Chen, Shouming, Qiu, Fangjun, Chen, Peien, Chen, Shaoxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623542/
https://www.ncbi.nlm.nih.gov/pubmed/34831803
http://dx.doi.org/10.3390/ijerph182212037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623542/
https://www.ncbi.nlm.nih.gov/pubmed/34831803
http://dx.doi.org/10.3390/ijerph182212037

Ejemplares similares